Literature DB >> 34158606

Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma.

Jordan Hindson1.   

Abstract

Entities:  

Year:  2021        PMID： 34158606     DOI： 10.1038/s41575-021-00484-8

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Authors:  Yelena Y Janjigian; Kohei Shitara; Markus Moehler; Marcelo Garrido; Pamela Salman; Lin Shen; Lucjan Wyrwicz; Kensei Yamaguchi; Tomasz Skoczylas; Arinilda Campos Bragagnoli; Tianshu Liu; Michael Schenker; Patricio Yanez; Mustapha Tehfe; Ruben Kowalyszyn; Michalis V Karamouzis; Ricardo Bruges; Thomas Zander; Roberto Pazo-Cid; Erika Hitre; Kynan Feeney; James M Cleary; Valerie Poulart; Dana Cullen; Ming Lei; Hong Xiao; Kaoru Kondo; Mingshun Li; Jaffer A Ajani
Journal:  Lancet       Date:  2021-06-05       Impact factor: 79.321
  1 in total
  2 in total

1.  Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.

Authors:  Xiaofang Xing; Jinyao Shi; Yongning Jia; Yunsheng Dou; Zhongwu Li; Bin Dong; Ting Guo; Xiaojing Cheng; Xiaomei Li; Hong Du; Ying Hu; Shuqin Jia; Jian Zhang; Ziyu Li; Jiafu Ji
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

Review 2.  From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.

Authors:  Jiangang Sun; Xiaojing Li; Peng Chen; Yongshun Gao
Journal:  J Inflamm Res       Date:  2022-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.